Abstract
We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4-40.6). Results confirm intravenous peramivir's usefulness.
Keywords:
Aging; Antiviral drugs; Geriatrics; Gerontology; High-risk patient; Neuraminidase inhibitor.
Copyright © 2017. Published by Elsevier B.V.
MeSH terms
-
Acids, Carbocyclic
-
Administration, Intravenous
-
Aged
-
Aged, 80 and over
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / adverse effects*
-
Cyclopentanes / administration & dosage*
-
Cyclopentanes / adverse effects*
-
Drug-Related Side Effects and Adverse Reactions / epidemiology
-
Female
-
Guanidines / administration & dosage*
-
Guanidines / adverse effects*
-
Humans
-
Influenza, Human / drug therapy*
-
Male
-
Retrospective Studies
-
Treatment Outcome
Substances
-
Acids, Carbocyclic
-
Antiviral Agents
-
Cyclopentanes
-
Guanidines
-
peramivir